DHFR-IN-25 (Compound N2) is a type of inhibitor of dihydrofolate reductase (DHFR). DHFR-IN-25 is a broad-spectrum and highly effective antibacterial agent, particularly showing significant effects on Candida albicans and Staphylococcus aureus. DHFR-IN-25 can be used for the study of local anti-infection.

DHFR-IN-24, a benzothiazole derivative, is a dihydrofolate reductase (DHFR) inhibitor. DHFR-IN-24 has intrinsic antibacterial activity against both Gram-positive and Gram-negative strains. DHFR-IN-24 synergistically combines DHFR inhibition with photodynamic therapy (PDT) for enhanced antibacterial activity against multidrug-resistant pathogens.

DHAD-IN-2 (compound 6ag) is a potent dihydroxy acid dehydratase (DHAD) inhibitor with a KD of 20 μM. DHAD-IN-2 demonstrates over 85% control effectiveness against Eclipta prostrata, Amaranthus retroflexus, and Setaria viridis at a dosage of 150 g ai/ha, while also showing safety for rice. DHAD-IN-2 can be used for herbicide research.

DGK-IN-13 is a DGK inhibitor. DGK-IN-13 can be used for the research of cancer.

DGK-IN-10 is a DGK inhibitor with IC50 values of ≤ 10 nM for both DGKα and DGKζ. DGK-IN-10 can be used for the research of diseases including cancer.

DFCI-002-06 is an orally active dual-target HCK/BTK PROTAC degrader with DC₅₀ values for HCK and BTK of 1.3 and 4.5 nM respectively. DFCI-002-06 retains higher anti-tumor activity than the HCK/BTK dual-target inhibitor, inducing apoptosis in cancer cells. DFCI-002-06 can be used for the study of MYD88 mutant B-cell malignancies. (Pink: Src and Btk ligand ; Blue: Cereblon ligand ; Black: linker).

Dezaguanine is a purine analog. Dezaguanine exhibits antitumor activity in leukemia and breast cancer cells. Dezaguanine can be used in cancer-related research.

Desmethyl-K777 is a one of the main metabolites of K777.

Desmethylcitalopram hydrobromide (DCIT hydrobromide) is a drug impurity.

Desfluoro-BMS-694153 (Compound 3) is a calcitonin gene-related peptide receptor (CGRP receptor) antagonist, with a Ki value of 0.01 nM. Desfluoro-BMS-694153 has a significantly reduced risk of CYP3A4 inhibition, and its IC50 values for CYP3A4-BFC and CYP3A4-BZR are 36 and 6 μM respectively. Desfluoro-BMS-694153 can be used for research on migraines.

Desferrioxamine X3 is an agent that binds iron and aluminium.

Desferricoprogen is a hydrophobic fungal iron chelator siderophore. Desferricoprogen reduces atherosclerotic plaque formation and inhibits lipid peroxidation in aortic roots in ApoE−/− mice on an atherogenic diet. Desferricoprogen can lower the level of oxidized LDL (oxLDL) and inhibit oxLDL-induced HO-1, CD36, and TNF-α mRNA expression. Desferricoprogen inhibits TNF-α-induced endothelial cell activation, VCAM-1, ICAM-1 experssion and preserves endothelial monolayer integrity. Desferricoprogen can be used for the research of atherosclerosis.

Desamino lenalidomide-5-F is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. Desamino lenalidomide-5-F can be linked to a target protein ligand via a linker to form a PROTAC.

Dehatrine is a dibenzylisoquinoline alkaloid with antiplasmodial activity. Dehatrine can be found in the Indonesian medicinal plant Beilschmiedia madang. Dehatrine is applicable to malaria-related research.

Decyl phosphate is a selective LPA2 agonist (EC50: 1.8 μM) and LPA1/LPA3 antagonist. Decyl phosphate can be used in the research of blood disorders.

Decarboxy ciprofloxacin (Decarboxylated ciprofloxacin) is an antibacterial agent. Decarboxy ciprofloxacin displays antibacterial activities against Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Bacillus subtilis, Enterobacter cloacae, Serratia marcescens and especially potent activity against Escherichia coli.

Deacetoxyvinzolidine (KAR-2) is a bis-indol derivative with high anti-microtubular and anti-tumour activities. Deacetoxyvinzolidine exhibits high affinity for bovine purified brain tubulin (Kd of 3 μM) and inhibits microtubule assembly at a concentration of 10 nM. Deacetoxyvinzolidine does not possess anti-calmodulin activity. Deacetoxyvinzolidine can be used for the study of leukaemia.

D-DT/MIF-1-IN-1 (Compound 4h) is a non-competitive, non-covalent inhibitor of MIF-1 and D-DT, with IC50 values of 2.4 μM and 4.0 μM against D-DT, and an IC50 value of 9.8 μM against MIF-1. D-DT/MIF-1-IN-1 inhibits D-DT-induced phosphorylation of ERK and exerts antiproliferative activity in non-small cell lung cancer cells.

DDR1/2 IN-4 (Compound 37) is a selective dual DDR1 and DDR2 kinase inhibitor, with a pKi of 8.6 for DDR1 and a pKi of 8.2 for DDR2. DDR1/2 IN-4 functionally inhibits the kinase activities of DDR1 and DDR2. DDR1/2 IN-4 inhibits the release of MCP-1. DDR1/2 IN-4 can be used in studies related to idiopathic pulmonary fibrosis.

DDB-S does not alter the protein binding properties of ICG, but increases its clearance rate. DDB-S can increase liver blood flow. DDB-S can be used to observe changes in liver blood flow.

DdBIC is a pyroptosis inducer. DdBIC binds to Nur77 and triggers its translocation to mitochondria, activates SDHA to deplete succinyl-CoA, disrupts heme homeostasis, induces electron leakage, and elicits mitochondrial ROS production. DdBIC induces mitochondrial ROS that oxidatively activates OMA1, promotes OPA1 cleavage and its release into the cytoplasm, activates the integrated stress response via PERK, and ultimately activates granzyme B to cleave GSDMC. DdBIC can be used for the study of melanoma.

ddATP (2',3'-Dideoxyadenosine 5'-triphosphate), an active metabolite of 2',3'-dideoxyinosine, is a chain-elongating inhibitor of DNA polymerase. ddATP can be used for Sanger method for DNA sequencing and research of virus infection.

DCAF11 ligand-Linker Conjugate 1 is a conjugate of a DCAF11 ligand and a linker. DCAF11 ligand-Linker Conjugate 1 can be used for the synthesis of PROTAC LGF308.

Dasatinib (GMP Like) (BMS-354825 (GMP Like)) is Dasatinib produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy.

Danitracen (NSC 170955) is an orally active, CNS penetrant serotonin antagonist with antidepressant activity. Danitracen reduces serotonin levels in the cerebrum, cerebellum, medulla and the whole brain. Danitracen exhibits anticataleptic effects in rat catalepsy models. Danitracen can be used for catalepsy and depression research.

DAMPA methyl ester is an inhibitor of dihydrofolate reductase. DAMPA methyl ester can be studied in research on chemotherapy.

D-Alanine-13C3 ((R)-Alanine-13C3) is the 13C-labeled D-Alanine. D-Alanine is a weak GlyR (inhibitory glycine receptor) and PMBA agonist, with an EC50 of 9 mM for GlyR.

D-473 is an orally active, blood-brain barrier penetrant and serotonin-preferring reuptake inhibitor. D-473 inhibits serotonin, dopamine and norepinephrine transporters, and significantly elevates the extracellular levels of these three neurotransmitters in rat brain regions. D-473 exhibits definite antidepressant-like activity without inducing motor activation. D-473 is widely used in studies related to major depressive disorder.

CYP51-IN-32 is an antifungal agent with an IC50 of 0.331 μM against CYP51 of Candida albicans. CYP51-IN-32 releases hydrogen sulfide (H2S) and inhibits hyphal formation and biofilm development of Candida albicans. CYP51-IN-32 can be formulated into PEG-based nanovesicles. CYP51-IN-32 is applicable to the research of Candida albicans infection.

CYP11A1-IN-2 (Compound 61) is a selective cholesterol side-chain cleavage enzyme (CYP11A1) inhibitor. CYP11A1-IN-2 can inhibitor steroid biosynthesis and can be used for the research of steroid hormone-dependent cancers, such as prostate cancer.